We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Iris BioTechnologies Launches Proprietary Informatics Database, BioWindows™

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Iris BioTechnologies has launched its proprietary database, BioWindows™. A computer based survey program, BioWindows™ is designed for individuals to compile personalized in-depth profiles to help determine the most appropriate medical solution.

Each individual confidentially enters personal information, including demographics, medical history, and lifestyle choices, into a database. This survey, in combination with a specific tissue biopsy, allows for medical professionals to accurately assess the most optimal form of treatment. The database facilitates comparisons with a central repository of gene profiles to assist doctors and scientists in using targeted diagnostic to personalize medical treatments.

“The launch of our informatics system, BioWindows™, is paving the way for Iris’s debut in the public marketplace,” says Simon Chin, founder, chairman, and chief executive officer of Iris BioTechnologies. “It signifies a critical step for Iris as it evidences our team’s hard work and commitment to the company’s mission and to the field of personalized medicine.”

Iris BioTechnologies is dedicated to identifying gene expression patterns. By profiling genomic information using their patented Nano-BioChip™ and analyzing these patterns and important factors contained in the interactive BioWindows survey, Iris has designed a remarkably comprehensive personalized medicine platform.

“Our BioWindows™ platform, coupled with our proprietary Nano-BioChip™, will soon help to identify effective methods to optimize breast cancer treatment, reduce both disease risk and medical costs while ultimately improving the patient quality of life,” Chin continues. “The information garnered by our database will not only help patients and their families, but those in generations to follow. There is currently a void in our medical system when it comes to targeted, individualized treatment, and we believe we have the solution.”